Skip to main content

Table 2 Individuals responding to candidate antigens from clinical cohorts in Turkey and Ethiopia

From: Development of a proof of concept immunochromatographic lateral flow assay for point of care diagnosis of Mycobacterium tuberculosis

Results from Turkish clinical cohorts

Cohort

Clinical definition

Number (percentage) responding to antigen

  

ESAT-6

CFP8A

Acr: MPT83

ORF3

Any antigen

TB patients (n = 99)

Pulmonary (n = 91)

17 (18.6%)

9 (9.8%)

40 (43.9%)

5 (5.5%)

45 (45.5%)

 

Extra-pulmonary (n = 8)

0 (0%)

0 (0%)

2 (25%)

0 (0%)

2 (25%)

TB contacts (n = 48)

PPD+, known exposure (n = 48)

4 (8.5%)

2 (4.2%)

16 (33.3%)

2 (4.2%)

18 (37.5%)

Community controls (n = 153)

Symptomatic, non-TB (n = 8)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 

Healthy, no identified exposure (n = 145)

6 (4.2%)

2 (1.4%)

15 (9.1%)

1 (0.7%)

18 (11.8%)

Results from Ethiopian clinical cohorts

Cohort

Clinical definition

Number (percentage) responding to antigen

  

ESAT-6

CFP8A

Acr: MPT83

ORF3

Any antigen

TB patients (n = 79)

Pulmonary (n = 48)

9 (18.8%)

5 (10.4%)

24 (50.0%)

0 (0%)

26 (54.2%)

 

Extra-pulmonary (n = 31)

4 (12.9%)

2 (0.65%)

12 (38.7%)

0 (0%)

12 (38.7%)

TB contacts (n = 73)

Known exposure (n = 73)

4 (8.48%)

2 (4.16%)

19 (26.0%)

0 (0%)

21 (28.8%)

Community controls (n = 60)

Healthy, no identified exposure (n = 60)

6 (4.19%)

2 (1.39%)

12 (20.0%)

0 (0%)

16 (26.7%)